← ANALYST RATINGS · TIPRANKS
Replimune Group (REPL): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $18.50, the highest $21.00, the lowest $14.00. The average is +70.3% from the last price of $10.86.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.00 → $11.50−4.2% | Hold | +5.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $11.00−4.3% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $11.00−4.3% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $10.50−4.5% | Hold | −3.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $11.50−8.0% | Hold | +5.9% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.50 → $11.00−4.3% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 04:05 | — | |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $20.00 | Buy | +84.2% | Reiterated | 10.09.26on TipRanks Sep 11 08:55 | −7.8%next day −3.3% · 5 days −3.4% | ↗ |
| Unknown Analyst | Kempen & Co | $19.00 | Buy | +75.0% | Initiated | 10.09.26on TipRanks Sep 11 08:55 | −7.8%next day −3.3% · 5 days −3.4% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $20.00 → $21.00+5.0% | Buy | +93.4% | Assigned | 26.08.26on TipRanks 07:35 | +0.5%next day −2.4% · 5 days +0.8% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $24.00 | Buy | +121.0% | Reiterated | 17.08.26on TipRanks 11:16 | −1.8%next day +7.2% · 5 days +1.7% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $19.00 | Buy | +75.0% | Reiterated | 17.08.26on TipRanks 08:11 | −1.8%next day +7.2% · 5 days +1.7% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $14.00 | Buy | +28.9% | Reiterated | 07.08.26on TipRanks 11:27 | −6.8%next day +13.4% · 5 days +23.7% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $11.00 → $17.00+54.5% | Buy | +56.5% | Upgrade | 03.08.26on TipRanks Aug 4 05:24 | +4.9%next day −1.7% · 5 days +12.7% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | — | Buy | — | Upgrade | 31.07.26on TipRanks 05:10 | — | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | — | Sell | — | Downgrade | 13.04.26on TipRanks 06:15 | −65.3%next day +13.5% · 5 days +18.5% | ↗ |
| Peter Lawson★★★★★★★★★★#602 · hits 47% · avg +15.5% | Barclays | $3.00 | Hold | −72.4% | Reiterated | 21.10.25on TipRanks 04:10 | −9.4%next day +3.0% · 5 days +26.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Replimune Group
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $19.14 at a price of $13.24 (+44.6%); now: $19.14 at $10.86 (+76.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 3 | 3 | 3 |
| Buy | 0 | 2 | 5 | 10 | 8 | 5 |
| Hold | 4 | 5 | 4 | 3 | 1 | 0 |
| Sell | 3 | 3 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q2 2027, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.78 (from $-0.85 to $-0.66). Last quarter: $-0.72.
Best top-analyst consensus in the sector · Healthcare
About Replimune Group
- CEO: Sushil Patel
- Employees: 465
- 500 Unicorn Park Drive, Woburn, MA, 01801, US
- www.replimune.com
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Data from the stock’s TipRanks forecast page, read 4 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗